United States · FDA
FDA approval not reviewed here
Loading research and source information…
Fatty liver disease and MASH · Drug research
The registry reports active not recruiting. This is trial metadata, not an assessment of treatment benefit.
Evidence 1Content updated Nov 5, 2026 · Sources last checked Nov 17, 2026
Inclusion Criteria: * Age above or equal to 18 years at the time of signing informed consent. * Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to the screening visit (V1). * Histological evidence of fibrosis stage 2 or stage 3 according to the NASH CRN (Clinical Research Network) classification based on a central pathologist evaluation of the baseline liver biopsy. * A histological NAS (Non-alcoholic fatty liver disease Activity Score) above or equal to 4 with a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning based on a central pathologist evaluation of the baseline liver biopsy. Exclusion Criteria: * Documented causes of chronic liver disease other than non-alcoholic fatty liver disease (NAFLD) * Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A). * Presence or history of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at randomisation. * Known or suspected excessive consumption of alcohol (greater than 20 g/day for women or greater than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)). * Treatment with vitamin E (at doses greater than or equal to 800 IU/day) or pioglitazone or medications approved for treatment of NASH which has not been at a stable dose in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose from time of biopsy until screening. * Treatment with GLP-1 RAs in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, any treatment with GLP-1 RAs from time of biopsy until screening (V2A). * Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until screening.
This record covers only the linked trial population. This registry-based page does not review FDA approval or labeling.
FDA approval not reviewed here
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
registry · NCT04822181 · Structured source fields
Source date: Oct 13, 2026 · Checked: Nov 17, 2026
Evidence location: protocolSection: identificationModule, statusModule, conditionsModule, armsInterventionsModule, designModule, outcomesModule, eligibilityModule, contactsLocationsModule, sponsorCollaboratorsModule; hasResults
Status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Conditions: Non-alcoholic Steatohepatitis.
Open original sourceFatty liver disease and MASH
See FDA labeling for the approved population and indication; this page covers the trial population only.
FDA labeling has not been reviewed for this page. This does not mean the treatment is unapproved.
Approval is specific to the indication and population. It does not establish availability, reimbursement or suitability for an individual.
This study is continuing but is no longer enrolling new participants.
Read trial record and posted resultsStudy ages: 18 Years and older. Other eligibility criteria apply; see the full criteria above.
Study countries and territories (including sites that may be closed): Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, Denmark, France, Germany, Greece, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States.
Primary data collection: Apr 25, 2029 (estimated). This is not a results-release date.
No results-posting date in this record.
Evidence 1registry · Registry metadata is submitted by the sponsor or responsible party and does not independently validate efficacy.
No posted registry results are indicated in this source response. This does not establish that no results exist elsewhere.
Limitations: Outcomes, effect estimates, uncertainty and study quality have not been appraised. Consult original results and publications.
Evidence 1